ArticleThe American journal of pathology2004
Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines.
Article in The American journal of pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 123 citations in OpenAlex.
- The Epigenetic Architecture of Classical Hodgkin Lymphoma: Lineage Erasure, Immune Escape, and Therapeutic Reprogramming.Medicina (Kaunas, Lithuania) · 2026Review
- Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions.Cancers · 2023Review
- MORC4 plays a tumor-promoting role in colorectal cancer via regulating PCGF1/CDKN1A axis in vitro and in vivo.Cancer gene therapy · 2023Article
- Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells.Blood cancer discovery · 2023Article
- New molecular targets in Hodgkin and Reed-Sternberg cells.Frontiers in immunology · 2023Review
- Dissecting the roles and clinical potential of YY1 in the tumor microenvironment.Frontiers in oncology · 2023Review
- PCGF1 promotes epigenetic activation of stemness markers and colorectal cancer stem cell enrichment.Cell death & disease · 2021Article
- HMGA1 induces EZH2 overexpression in human B-cell lymphomas.American journal of cancer research · 2021Article
- The biological implications of Yin Yang 1 in the hallmarks of cancer.Theranostics · 2020Review
- Co-inhibition of BMI1 and Mel18 enhances chemosensitivity of esophageal squamous cell carcinomaOncology letters · 2019Article
- Expression and Clinicopathological Significance of Mel-18 and Bmi-1 in Esophageal Squamous Cell Carcinoma.Technology in cancer research & treatment · 2017Article
- The Role of CtBP1 in Oncogenic Processes and Its Potential as a Therapeutic Target.Molecular cancer therapeutics · 2017Review
- NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.Oncogene · 2016Article
- Potential role of hypoxia in early stages of Hodgkin lymphoma pathogenesis.Haematologica · 2015Article
- Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma.Oncoimmunology · 2014Article
- Expression and clinicopathological significance of Mel-18 mRNA in colorectal cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Gene set enrichment analysis of the NF-κB/Snail/YY1/RKIP circuitry in multiple myeloma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- The role of maintenance proteins in the preservation of epithelial cell identity during mammary gland remodeling and breast cancer initiation.Chinese journal of cancer · 2014Review
- Pathobiology of hodgkin lymphoma.Mediterranean journal of hematology and infectious diseases · 2014Review
- Polycomb-group proteins in hematopoietic stem cell regulation and hematopoietic neoplasms.Leukemia · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human Polycomb-group (PcG) genes play a crucial role in the regulation of embryonic development and regulation of the cell cycle and hematopoiesis. PcG genes encode proteins that form two distinct PcG complexes, involved in maintenance of cell identity and gene silencing patterns. We recently showed that expression of the BMI-1 and EZH2 PcG genes is separated during normal B-cell development in germinal centers, whereas Hodgkin/Reed-Sternberg (H/RS) cells co-express BMI-1 and EZH2. In the current study, we used immunohistochemistry and immunofluorescence to determine whether the binding partners of these PcG proteins are also present in H/RS cells and H/RS-derived cell lines. PcG expression profiles were analyzed in combination with expression of the cell cycle inhibitor p16INK4a, because experimental model systems indicate that p16 is a downstream target of Bmi-1. We found that H/RS cells and HL-derived cell lines co-express all core proteins of the two known PcG complexes, including BMI-1, MEL-18, RING1, HPH1, HPC1, and -2, EED, EZH2, YY1, and the HPC2 binding partner, CtBP. Expression of HPC1 has not been found in normal mature B cells and other malignant lymphomas of B-cell origin, suggesting that the PcG expression profile of H/RS is unique. In contrast to Bmi-1 transgenic mice where p16INK4a is down-regulated, 27 of 52 BMI-1POS cases of HL revealed strong nuclear expression of p16INK4a. We propose that abnormal expression of BMI-1 and its binding partners in H/RS cells contributes to development of HL. However, abnormal expression of BMI-1 in HL is not necessarily associated with down-regulation of p16INK4a.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.